ISIS Pharmaceuticals CEO Unloads $488,480 in Stock (ISIS)

Share on StockTwits

ISIS Pharmaceuticals (NASDAQ:ISIS) CEO Stanley T. Crooke sold 16,000 shares of ISIS Pharmaceuticals stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $30.53, for a total transaction of $488,480.00. Following the completion of the sale, the chief executive officer now directly owns 6,941 shares of the company’s stock, valued at approximately $211,909. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) opened at 30.40 on Friday. ISIS Pharmaceuticals has a 52-week low of $22.25 and a 52-week high of $62.66. The stock has a 50-day moving average of $32.45 and a 200-day moving average of $38.23. The company’s market cap is $3.574 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.04. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $35.12 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The company’s revenue for the quarter was down 35.0% on a year-over-year basis. On average, analysts predict that ISIS Pharmaceuticals will post $-0.71 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on ISIS shares. Analysts at Zacks reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Thursday, June 5th. They now have a $29.00 price target on the stock. Separately, analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. Finally, analysts at TheStreet downgraded shares of ISIS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $41.10.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

Horizon Pharma Moves Overseas Defying Lawmakers
Horizon Pharma Moves Overseas Defying Lawmakers
Apple Frenzy as Stores Start Selling iPhone 6
Apple Frenzy as Stores Start Selling iPhone 6
GlaxoSmithKline Fined Close to $500 Million by China
GlaxoSmithKline Fined Close to $500 Million by China
Japan Sees Another Trade Deficit
Japan Sees Another Trade Deficit
Sony Says Losses Will Reach $2 Billion
Sony Says Losses Will Reach $2 Billion
UK Inflation Drops During August
UK Inflation Drops During August


Leave a Reply

 
 
© 2006-2014 Ticker Report. Google+.